SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Shares of MLTX are trending amid a steep decline following mixed results from a Phase 3 trial, leading to significant community discussion around potential short covering and whether the market has overreacted. Some investors are speculating about a possible acquisition by Merck, while others are assessing the company's cash reserves and future prospects. The conversation highlights the volatile nature of biotech stocks and the high-risk, high-reward potential in the sector.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

APDN is trending following news of a $58M private placement to initiate a BNB-focused digital asset strategy, with plans to change its ticker to BNBX; the stock experienced multiple trading halts as a result. The community is discussing the potential for a significant price increase, with some drawing comparisons to other low-float runners and noting Scaramucci's involvement as an advisor. This activity occurs amid broader speculation about the company's strategic shift towards digital assets.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals ($AUPH) is trending due to an ex-FDA employee's LinkedIn post questioning the safety and efficacy of their drug Lupkynis, sparking concerns about potential market manipulation. The community is debating the validity of the claims, the company's response, and possible legal action. Some investors believe this is a strategic move to lower the price before a buyout, while others worry about the drug's reputation and future sales.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is trending as it reached new all-time highs, driven by optimism around its prediction markets business and expansion into new fintech services. Community members are actively discussing the stock's potential to continue its impressive run, while some caution against overvaluation and a possible pullback. Bullish sentiment is fueled by strong financials and the stock's inclusion in the S&P 500.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as investors eagerly anticipate the release of its Preliminary Feasibility Study (PFS), with some speculating its imminent arrival could trigger a significant price surge. Bullish sentiment is fueled by increasing volume, government backing, and potential short squeezes, while community members express excitement about the company's long-term prospects in the lithium and battery recycling sectors.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a 'culture coin' and a way to invest in the cannabis space. Community members are drawn to its focus on freedom, community, and growth, viewing it as more than just a token. Bullish sentiment is also fueled by broader discussions around potential cannabis legalization.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding Limited is trending amid high volatility, with community members debating whether it's primed for another surge or a pullback. Discussions revolve around its low float and potential for a short squeeze, while some caution against the risks associated with Chinese stocks. The stock's recent price action and potential technical patterns are also being closely watched by traders.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential to reclaim higher price levels, with some anticipating ETF approvals could act as a catalyst. Chatter includes discussion of meme coins built on the Solana blockchain and the overall bullish sentiment for "Uptober". Technical analysis suggests $SOL.X is showing signs of strength after bouncing off a key Fibonacci retracement level.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as the stock experiences notable price volatility, prompting discussions around potential bottom fishing and averaging down strategies among investors. Recent news of the COO's departure appears to be weighing on the stock, while some community members see a disconnect between the stock price and the company's fundamentals, citing solid growth and good earnings. Broader market sentiment around fast-casual restaurants and consumer spending is also influencing the conversation.

AKIRA LABS

AKIRA.X is trending alongside other tokens like WAGMI.X and SOL.X, with many users expressing bullish sentiment and referring to it as a potential "gem." The community seems to be focused on the potential for "meme season" profits and touting AKIRA.X as a better investment than others.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

Equity

Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition

Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships.
read more...

Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care

Psyence Biomed initiates a Phase IIb psilocybin trial in Australia to explore its potential as a treatment for Adjustment Disorder.
read more...

Psyence Biomedical Shares Clinical Ambitions

Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has released an investor presentation highlighting its focus on developing...

Psyence Biomedical Amends Note Agreements

Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has entered into an addendum with note holders, facilitating the conversio...

Why Psyence Biomedical (PBM) Stock Is Skyrocketing

Psyence Biomedical shares are trading higher by 73% during Thursday's session. The company announced the export of nature-derived psilocybin to Australia.
read more...

Psyence Biomedical Issues Convertible Note

Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has issued a Senior Secured Convertible Note due July 15, 2027, with a pri...

Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for...

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog Benefits are thought to include a...

Psyence Biomedical gets non-compliance notification from Nasdaq

Psyence Biomedical gets non-compliance notification from Nasdaq...

Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on February 25, 2021 and is headquartered in Toronto, Canada.

Psyence Biomedical Ltd.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$3.19
Prev Close	$3.11
Open	$3.11
Dividend Yield	0.00%
50-Day Moving Average	$4.25
Beta	1.89
Avg. Volume	2.99M
PE Ratio	-0.21

52-Week High	$82.49
52-Week Low	$2.36
Market Capitalization	$2.22M
EPS (Annual)	$1.78
Price to Book	-0.19
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PBM
Psyence Biomedical Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest PBM News

PBM Psyence Biomedical Ltd.